Description

Simple

A medication used to treat drooling, abdominal pain, a slow heartbeat, IBS (irritable bowel syndrome), and motion sickness.

Clinical

An anticholinergic used to treat excessive salivation, colicky abdominal pain, bradycardia, diverticulitis, IBS, and motion sickness.

Overview

An alkaloid from Solanaceae, especially Datura metel L. and Scopola carniolica. Scopolamine and its quaternary derivatives act as antimuscarinics like atropine, but may have more central nervous system effects. Among the many uses are as an anesthetic premedication, in urinary incontinence, in motion sickness, as an antispasmodic, and as a mydriatic and cycloplegic.

Pharmacology

Indication

For the treatment of excessive salivation, colicky abdominal pain, bradycardia, sialorrhoea, diverticulitis, irritable bowel syndrome and motion sickness.

Pharmacodynamic

Scopolamine is a muscarinic antagonist structurally similar to the neurotransmitter acetylcholine and acts by blocking the muscarinic acetylcholine receptors and is thus classified as an anticholinergic. Scopolamine has many uses including the prevention of motion sickness. It is not clear how Scopo... Read more

Mechanism of action

Scopolamine acts by interfering with the transmission of nerve impulses by acetylcholine in the parasympathetic nervous system (specifically the vomiting center).

Absorption

Bioavailability is 10 - 50%

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

4.5 hours

Route of elimination

Less than 10% of the total dose is excreted in the urine as parent and metabolites over 108 hours.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

  • Route:
    • Oral
  • Regions: US
  • Patient Conditions:
      • Name: Intestinal atony of the elderly or debilitated patient
      • Drugbank Id: DBCOND0107970
  • Route:
    • Oral
  • Regions: US
  • Patient Conditions:
      • Name: Unstable cardiovascular status in acute hemorrhage
      • Drugbank Id: DBCOND0107971
  • Route:
    • Oral
  • Regions: US
  • Patient Conditions:
      • Name: Severe Ulcerative Colitis
      • Drugbank Id: DBCOND0033634
      • Modification Of:
        • Base:
          • Name: Ulcerative Colitis
          • Drugbank Id: DBCOND0029012
        • Severity:
          • Includes:
            • severe
  • Route:
    • Oral
  • Regions: US
  • Patient Conditions:
      • Name: Toxic megacolon complicating ulcerative colitis
      • Drugbank Id: DBCOND0107747
  • Route:
    • Oral
    • Transdermal
  • Regions: US
  • Patient Conditions:
      • Name: Narrow-angle glaucoma
      • Drugbank Id: DBCOND0095646
  • Route:
    • Transdermal
  • Hypersensitivity:
    • belladonna alkaloids
  • Regions: US
  • Route:
    • Oral
  • Regions: US
  • Patient Conditions:
      • Name: Obstructive Uropathy
      • Drugbank Id: DBCOND0068646
  • Route:
    • Oral
  • Regions: US
  • Patient Conditions:
      • Name: Obstructive disease of the gastrointestinal tract
      • Drugbank Id: DBCOND0107746
  • Route:
    • Oral
  • Regions: US
  • Patient Conditions:
      • Name: Paralytic Ileus
      • Drugbank Id: DBCOND0047064
  • Route:
    • Oral
  • Regions: US
  • Patient Conditions:
      • Name: Myasthenia Gravis
      • Drugbank Id: DBCOND0028961

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Scopolamine
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1,10-Phenanthroline
The therapeutic efficacy of Scopolamine can be decreased when used in combination with 1,10-Phenanthroline.
2,5-Dimethoxy-4-ethylamphetamine
The risk or severity of Tachycardia can be increased when Scopolamine is combined with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with 5-methoxy-N,N-dimethyltryptamine.
7-Nitroindazole
The risk or severity of adverse effects can be increased when Scopolamine is combined with 7-Nitroindazole.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when Scopolamine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Abediterol
The risk or severity of Tachycardia can be increased when Scopolamine is combined with Abediterol.
Abemaciclib
The serum concentration of Abemaciclib can be increased when it is combined with Scopolamine.
Acebutolol
The serum concentration of Acebutolol can be increased when it is combined with Scopolamine.
Acepromazine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Aceprometazine.
Acetaminophen
The serum concentration of Acetaminophen can be increased when it is combined with Scopolamine.
Acetazolamide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Acetazolamide.
Acetophenazine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Acetophenazine.
Acetyldigoxin
Scopolamine may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.
Acetylglycinamide chloral hydrate
The risk or severity of adverse effects can be increased when Scopolamine is combined with Acetylglycinamide chloral hydrate.
Acetylsalicylic acid
The serum concentration of Acetylsalicylic acid can be increased when it is combined with Scopolamine.
Aclidinium
The risk or severity of adverse effects can be increased when Scopolamine is combined with Aclidinium.
1 References
  1. 1 . Putcha L, Cintron NM, Tsui J, Vanderploeg JM, Kramer WG: Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. Pharm Res. 1989 Jun;6(6):481-5.PubMed: 2762223